LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
The term 'Ozempic butt' describes the loss of volume and sagging appearance in the buttocks that some people notice during treatment with semaglutide (Ozempic) or similar GLP-1 receptor agonists. Whilst not a formal medical diagnosis or recognised adverse reaction, this phenomenon reflects the body contour changes that can accompany significant weight loss. Ozempic is licensed in the UK for type 2 diabetes management, and its appetite-suppressing effects often lead to weight reduction. Understanding what these changes look like, why they occur, and when to seek medical advice can help patients maintain realistic expectations during treatment.
Quick Answer: 'Ozempic butt' describes flattened, sagging buttocks with loose skin resulting from rapid fat loss during semaglutide treatment, not a specific drug effect.
'Ozempic butt' is a colloquial term used to describe the loss of volume and sagging appearance in the buttocks that some individuals experience during treatment with semaglutide (Ozempic) or similar GLP-1 receptor agonists. Whilst not a formal medical diagnosis or a recognised adverse reaction in the Ozempic Summary of Product Characteristics (SmPC), this phenomenon has gained attention as these medications have become increasingly prescribed.
Ozempic (semaglutide) is licensed in the UK specifically for the treatment of type 2 diabetes. A different semaglutide formulation, Wegovy, is licensed for weight management. Ozempic works by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that regulates blood glucose levels and appetite. By binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, semaglutide enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. These combined effects often lead to weight loss, which is beneficial for glycaemic control in appropriate patients. In adults with type 2 diabetes and established cardiovascular disease, semaglutide may also reduce cardiovascular risk.
However, rapid or substantial weight loss from any cause—whether medication, dietary changes, or illness—can result in loss of both adipose (fat) tissue and lean muscle mass. The buttocks contain considerable fat deposits that provide shape and volume. When this fat is lost quickly, the overlying skin may not contract at the same rate, particularly in older adults or those with reduced skin elasticity. This mismatch creates a deflated, sagging appearance.
It is important to emphasise that there is no official medical link between semaglutide and specific fat loss patterns in the buttocks. The changes observed are consistent with generalised weight loss rather than a unique drug effect. The term 'Ozempic butt' reflects patient experiences and social media discourse rather than established clinical terminology.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
The physical appearance of 'Ozempic butt' varies between individuals but typically involves several characteristic features related to volume loss and skin laxity. Understanding these changes can help patients recognise what is a normal consequence of weight loss versus signs requiring medical attention.
Common visual features include:
Loss of volume and projection – The buttocks may appear flatter and less rounded than before treatment, with reduced prominence when viewed from the side
Sagging or drooping skin – Excess skin may hang or fold, particularly at the lower portion of the buttocks where gravitational effects are most pronounced
Visible skin creases or folds – New horizontal lines or creases may develop where skin has lost underlying support
Altered contour and shape – The smooth, curved outline may become irregular or angular, with more visible bony prominences
Textural changes – The skin may appear looser, crepey, or less firm to touch
The severity of these changes typically correlates with the amount and rate of weight loss. Individuals who lose weight gradually (0.5–1 kg per week, as recommended by NHS Better Health guidance) may experience less dramatic changes than those with rapid weight reduction. The appearance may be more pronounced in people with pre-existing skin laxity, older adults, or those who have lost substantial amounts of weight.
It is worth noting that similar changes can affect other body areas during significant weight loss, including the face, arms, abdomen, and thighs. The buttocks may simply be more noticeable due to their role in body contour and clothing fit. These changes are usually medically harmless, though skin folds can sometimes cause intertrigo (inflammation in skin folds), irritation or infection requiring medical attention. Some individuals may also experience psychological impacts related to body image changes.
Whilst anyone experiencing significant weight loss on semaglutide may notice changes in body contour, certain factors increase the likelihood of developing noticeable volume loss and skin laxity in the buttocks and other areas.
Age and skin elasticity represent primary risk factors. Older adults naturally have reduced collagen and elastin in their skin, which diminishes the skin's ability to contract after fat loss. Individuals over 50 years are particularly susceptible to loose skin following weight reduction. Conversely, younger patients typically have better skin elasticity and may experience less visible sagging.
The magnitude and speed of weight loss significantly influence outcomes. Rapid weight loss gives skin insufficient time to adapt to the body's new contours. Patients losing substantial amounts of weight are more likely to notice pronounced changes. NHS Better Health guidance recommends gradual, sustainable weight loss of 0.5–1 kg weekly to optimise health outcomes and minimise adverse effects.
Baseline body composition matters considerably. Individuals with higher initial body fat percentages have more adipose tissue to lose, potentially resulting in more dramatic contour changes. Those with lower muscle mass may also experience more visible effects, as muscle provides structural support beneath the skin.
Additional risk factors include:
Previous significant weight fluctuations or yo-yo dieting
Genetic factors affecting skin quality and collagen production
Smoking history, which impairs skin elasticity
Inadequate protein intake during weight loss, leading to muscle loss
Insufficient resistance exercise to maintain muscle mass
Dehydration or poor nutritional status
Patients with multiple risk factors should discuss realistic expectations with their GP or diabetes specialist nurse before commencing semaglutide therapy. Incorporating resistance training and adequate protein intake may help preserve muscle mass and improve body composition during weight loss. A registered dietitian can provide personalised advice on protein requirements, which vary based on age, activity level and kidney function.
Whilst changes in body contour during weight loss are generally expected and not medically concerning, certain situations warrant discussion with your GP or healthcare team. Distinguishing between normal physiological changes and those requiring clinical attention is important for safe medication use.
You should contact your GP if you experience:
Weight loss that is faster than expected or causing functional problems
Signs of malnutrition – Extreme fatigue, hair loss, brittle nails, persistent dizziness, or difficulty concentrating may suggest inadequate nutritional intake
Muscle weakness or difficulty with daily activities – Significant loss of muscle mass can impair function and increase fall risk, particularly in older adults
Skin changes beyond sagging – Rashes, persistent redness, breakdown, or infection in skin folds require assessment
Psychological distress – If body image concerns are affecting your mental health, quality of life, or medication adherence, support is available
Seek urgent medical advice if you develop:
Severe, persistent abdominal pain (which could indicate pancreatitis)
Persistent vomiting or signs of dehydration
Symptoms of gallstones (pain in upper right abdomen, nausea)
Signs of kidney problems (reduced urination, swelling, fatigue)
Your GP can assess whether your weight loss trajectory is appropriate for your individual circumstances and may refer you to a dietitian for nutritional optimisation or to physiotherapy for exercise guidance. They can also review your semaglutide dose and discuss whether adjustments might slow the rate of weight loss whilst maintaining glycaemic control.
For patients significantly troubled by skin laxity, referral to dermatology or plastic surgery services may be appropriate, though such interventions are rarely available through the NHS for cosmetic concerns alone. Non-surgical options such as radiofrequency treatments or dermal fillers exist privately, though evidence for their effectiveness varies and safety checks are essential before pursuing these treatments.
Remember that body composition changes are a normal part of weight loss. Setting realistic expectations and focusing on the metabolic health benefits of appropriate semaglutide treatment can help maintain perspective. Your healthcare team is available to support you throughout your treatment journey.
If you suspect you are experiencing any side effects from semaglutide, report them via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app).
No, 'Ozempic butt' is not a formal medical diagnosis or recognised adverse reaction in the Ozempic Summary of Product Characteristics. It is a colloquial term describing body contour changes consistent with generalised weight loss rather than a specific drug effect.
Gradual weight loss (0.5–1 kg weekly), resistance training to preserve muscle mass, and adequate protein intake may help minimise skin laxity and volume loss. Discuss personalised strategies with your GP or a registered dietitian.
Contact your GP if you experience faster-than-expected weight loss, signs of malnutrition, muscle weakness affecting daily activities, skin infections in folds, or psychological distress related to body image changes.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
